Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/13/2018 06/14/2018 06/15/2018 06/18/2018 06/19/2018 Date
122.63(c) 122.41(c) 122.61(c) 121.32(c) 122.57 Last
5 836 904 5 239 195 13 173 510 6 787 408 8 572 409 Volume
+0.07% -0.18% +0.16% -1.05% +1.03% Change
More quotes
Financials (USD)
Sales 2018 81 525 M
EBIT 2018 24 885 M
Net income 2018 16 158 M
Debt 2018 10 673 M
Yield 2018 2,97%
Sales 2019 84 061 M
EBIT 2019 26 484 M
Net income 2019 18 657 M
Finance 2019 4 070 M
Yield 2019 3,17%
P/E ratio 2018 17,57
P/E ratio 2019 16,22
EV / Sales2018 4,16x
EV / Sales2019 3,86x
Capitalization 329 B
More Financials
Company
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field.It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices.The Consumer segment includes products used in the baby care,... 
Sector
Pharmaceuticals
Calendar
06/23 | 06:30pmPresentation
More about the company
Surperformance© ratings of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
Latest news on JOHNSON & JOHNSON
12:04aJOHNSON & JOHNSON : Pa. court backs $12.8M verdict against Johnson & Johnson sub..
AQ
06/19JOHNSON & JOHNSON : to Host Investor Conference Call on Second-Quarter Results
PR
06/18MARKETS RIGHT NOW : Stocks look to recover from early skid
AQ
06/18JOHNSON & JOHNSON : FDA Approves the Next Generation of Customized LASIK Treatme..
PU
06/18JOHNSON & JOHNSON : Janssen Pharmaceutical - XARELTO Associated with Significant..
AQ
06/16JOHNSON & JOHNSON : Gift Provides Undergraduate Financial Aid and Serves Communi..
AQ
06/15JOHNSON & JOHNSON : XARELTO (rivaroxaban) Associated With Significantly Reduced ..
AQ
06/15JOHNSON & JOHNSON : XARELTO (rivaroxaban) Associated with Significantly Reduced ..
AQ
06/15KYROS LAW IS INVESTIGATING CLAIMS ON : 1,100 Invokana Lawsuits Alleging Diabetic..
PR
06/14JOHNSON & JOHNSON : Innovation Announces Five-Year Alliance with Boston Universi..
AQ
More news
Sector news : Pharmaceuticals - NEC
06/19High Times refreshes IPO plans as cannabis companies build buzz on Wall Stree..
RE
06/19MERCK : to Distribute HistoCyte Laboratories Products
DJ
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
06/19Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
RE
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on JOHNSON & JOHNSON 
JOHNSON & JOHNSON - 2017
The underlying trend is to the upside
BUY
JOHNSON & JOHNSON - 2017
Expect the comeback of a strong trend
BUY
More Strategies
Qtime:1
News from SeekingAlpha
06/1919 'Safer' Dividends From My Readers 36 Most Mentioned June Dividend Stocks 
06/19DIVIDEND SENSEI'S PORTFOLIO UPDATE 3 : 3 Reasons You Should Avoid This Dangerous.. 
06/19The Market Needs A Glum Index - Cramer's Mad Money (6/18/18) 
06/19Readers Wrote-Up 37 Dividend Stocks In May-June Comments 
06/18Jane's May Dividend Income Tracker - Retirement Accounts 
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 144 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
MERCK AND COMPANY8.39%166 880
AMGEN6.39%122 422